PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.61, $0.07 better than the analyst estimate of $0.54. Revenue for the quarter came in at $178.1 million versus the consensus estimate of $149.2 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.